Myeloma Tests Could Confuse Doctors into Suspecting Relapse, Study Argues
Lab tests used to evaluate treatment response after a stem cell transplant for multiple myeloma could lead physicians to wrongfully believe that a patient is…
News
Safety Concerns About Other Therapies Prompt FDA to Put a Hold on Three Opdivo Combo Trials
The U.S. Food and Drug Administration has ordered Bristol-Myers Squibb to put a hold on three clinical trials evaluating Opdivo (nivolumab) in combination with…
FDA Halts Imfinzi Combination Trials After Unexplained Keytruda-related Deaths
The U.S. Food and Drug Administration (FDA) suspended a Phase 1 clinical trial testing a combination of AstraZeneca‘s Imfinzi (durvalumab) with an immunomodulatory and an anti-cancer…
Long-term Data Confirms Kyprolis Survival Benefit in Relapsed Myeloma Patients
New long-term data from the Phase 3 ENDEAVOR trial has shown that relapsed multiple myeloma patients treated with Kyprolis (carfilzomib) plus dexamethasone survive a median of…
Kyprolis Combo Treatment Extends Survival of Relapsed Myeloma Patients, ENDEAVOR Study Shows
Relapsed multiple myeloma patients who receive Kyprolis (carfilzomib) plus dexamethasone as their second-to-fourth treatment regimen survive a median of 7.6 months longer than those…
Darzalex Combos Might Be More Efficient When Used Early in Myeloma
Patients with relapsed or treatment-resistant multiple myeloma, who have undergone several earlier treatment rounds, have a much poorer response to combination treatments including Darzalex (daratumumab)…
Darzalex Combo Therapy Found to Reduce Risk of Myeloma Progression or Death by Half in Newly-diagnosed Patients
Newly-diagnosed multiple myeloma patients who are not eligible for a stem cell transplant reduce the risk of disease progression or death by half when Darzalex (daratumumab)…
BioLineRx’s Stem Cell Mobilization Therapy BL-8040 to Enter Phase 3 Trial
BioLineRx is seeking regulatory approval to advance into a Phase 3 clinical trial its treatment BL-8040, for blood stem cell mobilization to prepare for autologous…
Kite Pharma Asks FDA to Pave Way Toward It Holding Clinical Trials of Its Myeloma Therapy KITE-585
Kite Pharma has submitted an investigational new drug application to the U.S. Food and Drug Administration that would pave the way toward clinical trials of its…
Scottish Medicines Consortium Approves Kyprolis-Dexamethasone Combo for Previously Treated Multiple Myeloma Patients
Combining the proteasome inhibitor Kyprolis (carfilzomib) with dexamethasone is beneficial for adult patients with multiple myeloma who have received…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML